# Tesamorelin Before and After: What the Visceral-Fat Trials Measured > Tesamorelin before and after: not testimonials, but the measured VAT, triglyceride, IGF-1, and hepatic-fat changes from the pivotal RCTs — 15.2% visceral-fat reduction at 26 weeks, logged and cited. Not personal testimonials — the actual deltas the randomized trials recorded: visceral fat, triglycerides, IGF-1, and hepatic fat, each with its population and its scope printed beside it. ## The short version When people search "tesamorelin before and after" they usually want pictures. This page gives numbers instead, because that is what the trials produced. The before-and-after that matters is a CT or MRI measurement of visceral fat (the deep belly fat around the organs), and across the pivotal trial it dropped 15.2% in 26 weeks while placebo went up 5.0% [1]. Triglycerides fell, IGF-1 rose, and liver fat dropped in a separate study [1][3]. Two honest caveats the data is firm on: every result is from people with HIV-related fat buildup, and the fat comes back when dosing stops [2][6]. ## Tesamorelin results: measured outcomes across trials The tesamorelin results that anchor the record are imaging-based fat measurements, not scale weight. In the pivotal 26-week Phase 3 RCT of 412 HIV patients with abdominal fat accumulation, tesamorelin 2 mg/day reduced visceral adipose tissue by 15.2% while placebo rose 5.0%; triglycerides decreased 50 mg/dL (vs +9 mg/dL placebo) and IGF-1 increased 81.0% [1]. Over the 52-week program the VAT reduction was sustained at -18% versus baseline, and changes in glucose parameters over the year were not clinically significant [2]. The pooled odds tell the same story: across two Phase 3 RCTs (543 tesamorelin vs 263 placebo), the odds of reducing VAT below 140 cm² were 3.9-fold greater with tesamorelin (95% CI 2.03–7.44); baseline metabolic syndrome, triglycerides >1.7 mmol/L, and white race predicted response [10]. The 2026 meta-analysis of five RCTs pooled the effect at -27.71 cm² visceral fat, -1.18 kg trunk fat, -4.28% hepatic fat, and +1.42 kg lean mass [13]. These are the [visceral-fat trial results](/before-and-after) in aggregate — measured, pooled, and bounded by the population they came from. ## Selective for visceral fat — and the liver The before-and-after signature is selectivity. Tesamorelin reduced visceral adipose tissue (the fat around the organs) without significantly changing subcutaneous fat (the fat beneath the skin) or BMI in the studied trials [1]. It also improved fat *quality*: over 26 weeks it raised VAT and SAT density on CT (VAT +6.2 vs +0.3 HU placebo; SAT +4.0 vs +0.3 HU; both P<0.0001), an adipocyte-quality gain independent of fat-quantity change [9]. In HIV-associated fatty liver, the JAMA RCT recorded a -42 cm² visceral-fat treatment effect (P=0.005) alongside a net -2.9% hepatic-fat reduction (P=0.003) [3]. The metabolic dividend was proportional to the fat loss: responders who hit at least 8% VAT reduction showed greater triglyceride reductions and a better metabolic profile than non-responders [7], and the inflammatory-marker improvements tracked VAT reduction rather than a direct GH effect [8]. The body-composition picture is a redistribution — visceral and hepatic fat down, lean mass modestly up [13] — not a generalized weight-loss result. ## The before-and-after that is not on a scale Because tesamorelin reduces visceral fat without significantly changing BMI [1], the most informative "before and after" is metabolic, not the bathroom scale. Triglycerides fell 50 mg/dL in the pivotal trial against a 9 mg/dL rise on placebo [1], and the responders who achieved at least 8% VAT reduction showed the largest triglyceride improvements and the most favorable overall metabolic profile [7]. The inflammatory "after" is subtler but consistent: tesamorelin reduced tissue plasminogen activator antigen and modestly raised adiponectin, with the inflammatory-marker changes tracking the degree of VAT reduction rather than a direct GH effect — evidence that visceral fat is the mediator, not a bystander [8]. The 2023 post-hoc analysis added that the VAT and waist-circumference reductions held regardless of whether patients had dorsocervical fat accumulation (P=0.657), so the before-and-after did not depend on that subgroup feature [12]. The honest reading is a metabolic redistribution captured by imaging and bloodwork, bounded by the HIV-lipodystrophy population it was measured in. ## How long does it take, and what happens when you stop? The trials measured visceral-fat reduction over 26 weeks, with reduction sustained at 52 weeks on continued dosing [1][2]. The 2026 five-RCT meta-analysis pooled visceral, trunk, and hepatic-fat changes across these multi-month treatment periods [13]. There is no published evidence for a rapid, weeks-scale cosmetic transformation; the effect is a months-long shift measured by imaging. The durability caveat is firm and repeatedly documented. In the 52-week program, visceral fat reaccumulated upon discontinuation [2], and the Phase 3 trial with a safety extension likewise reported reversal of the visceral-fat reduction after stopping [6]. The measured benefit was contingent on continued dosing — the "after" reverts toward the "before" once the drug is withdrawn. Any general-population fat-loss extrapolation also carries an honest gap: no large general-population fat-loss RCT has been completed, so non-HIV efficacy is mechanistically plausible but not established [4]. --- A terminal trace of the peer-reviewed tesamorelin record — every visceral-fat and IGF-1 figure returned green and sourced, the HIV-lipodystrophy-only scope and the reverts-when-you-stop caveat printed beside the value, never behind it; no clinic at this prompt and nothing here dosed, dispensed, or sold.